138 related articles for article (PubMed ID: 7330671)
1. Radiographic evaluation of therapeutic response in bony metastases of breast cancer.
Libshitz HI; Hortobagyi GN
Skeletal Radiol; 1981; 7(3):159-65. PubMed ID: 7330671
[TBL] [Abstract][Full Text] [Related]
2. Response to chemotherapy of breast carcinoma bone metastases: assessment by bone scan.
Brufman G; Schächner E; Biran S
Diagn Imaging; 1979; 48(1):49-52. PubMed ID: 535514
[TBL] [Abstract][Full Text] [Related]
3. [Criteria for evaluating the efficacy of treatment of breast cancer metastases to the bones].
Lichinitser MR; Vyshinskaia GV; Gritsaĭ AA; Kondrat'eva AP; Luk'ianchenko AB
Med Radiol (Mosk); 1986 Feb; 31(2):28-31. PubMed ID: 3951344
[TBL] [Abstract][Full Text] [Related]
4. Osseous metastases in breast cancer: radiographic monitoring of therapeutic response.
Huber S; Ulsperger E; Gomar C; Koderhold G; Czembirek H
Anticancer Res; 2002; 22(2B):1279-88. PubMed ID: 12168938
[TBL] [Abstract][Full Text] [Related]
5. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer.
Smalley RV; Lefante J; Bartolucci A; Carpenter J; Vogel C; Krauss S
Breast Cancer Res Treat; 1983; 3(2):209-20. PubMed ID: 6688538
[TBL] [Abstract][Full Text] [Related]
6. Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma.
Harvey HA
Cancer; 1997 Oct; 80(8 Suppl):1646-51. PubMed ID: 9362431
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of serial bone scans in assessing response to chemotherapy in advanced breast cancer.
Bitran JD; Bekerman C; Desser RK
Cancer; 1980 Apr; 45(7):1562-8. PubMed ID: 7370916
[TBL] [Abstract][Full Text] [Related]
8. [Combination of aminoglutethimide and polychemotherapy for the treatment of predominant bone metastasis in breast cancer].
Rieche K; Dabag S; Scharlau L
Dtsch Med Wochenschr; 1986 Nov; 111(45):1726-9. PubMed ID: 3780435
[TBL] [Abstract][Full Text] [Related]
9. [Bone metastasis of breast cancer. Apropos of a series of 50 cases].
Vincent-Joyeux F; Bontoux D; Alcalay M; Daban A; Vincent D
Sem Hop; 1982 Dec; 58(48):2827-31. PubMed ID: 6302849
[TBL] [Abstract][Full Text] [Related]
10. Assessment of response of bone metastases to systemic treatment in patients with breast cancer.
Coombes RC; Dady P; Parsons C; McCready VR; Ford HT; Gazet JC; Powles TJ
Cancer; 1983 Aug; 52(4):610-4. PubMed ID: 6861098
[TBL] [Abstract][Full Text] [Related]
11. [Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer].
Abe O; Izuo M; Enomoto K; Kubo K; Koyama H; Sakai K; Terasawa T; Tominaga T; Nomura Y
Gan To Kagaku Ryoho; 1982 May; 9(5):866-73. PubMed ID: 7184431
[TBL] [Abstract][Full Text] [Related]
12. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer.
Koizumi M; Matsumoto S; Takahashi S; Yamashita T; Ogata E
Clin Nucl Med; 1999 Jan; 24(1):15-20. PubMed ID: 9890487
[TBL] [Abstract][Full Text] [Related]
13. [Adriablastin (doxorubicin) in the combined chemotherapy of patients with disseminated forms of breast cancer].
Voznyĭ EK; Besova NS; Kurkina TV; Al'tshtuller IuB
Antibiotiki; 1984 Jun; 29(6):463-8. PubMed ID: 6476811
[TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
Nomura Y; Tominaga T; Adachi I; Koyama H; Fukami A
Gan To Kagaku Ryoho; 1994 Sep; 21(12):1949-56. PubMed ID: 8085846
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy in the management of breast cancer metastases.
Deemarsky LY; Chernomordikova MF
Cancer; 1970 Oct; 26(4):771-9. PubMed ID: 5506600
[No Abstract] [Full Text] [Related]
16. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
[TBL] [Abstract][Full Text] [Related]
17. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.
De Lena M; Brambilla C; Morabito A; Bonadonna G
Cancer; 1975 Apr; 35(4):1108-15. PubMed ID: 1116104
[TBL] [Abstract][Full Text] [Related]
18. An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer.
Creech RH; Catalano RB; Mastrangelo MJ; Engstrom PF
Cancer; 1975 Apr; 35(4):1101-7. PubMed ID: 1116103
[TBL] [Abstract][Full Text] [Related]
19. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
[TBL] [Abstract][Full Text] [Related]
20. Advanced breast cancer with bone-only metastases: a chemotherapeutically responsive pattern of metastases.
Smalley RV; Scogna DM; Malmud LS
Am J Clin Oncol; 1982 Apr; 5(2):161-6. PubMed ID: 7091041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
